Demonstration of a repeatable pooled lentiviral sgRNA screen in primary human T cells
32 result(s)
Achieve DNA-free guaranteed gene editing with synthetic predesigned sgRNA reagents and libraries covering the entire human genome.
Check out the BioIT Beta Tools page to test tools created by our BioIT team!
利用できる多くの選択肢の中から最適なセルベーススクリーニングを選ぶことはたちまちに意思決定が複雑になることがあります。ここでは、主な選択肢である細胞パネルスクリーニングと機能ゲノミクススクリーニングを概観します。
Functional genomic screening libraries that represent the most current findings within the field
CRISPR-Cas9 lentiviral sgRNA pooled screening changes everything.
The clinical success rate of new oncology drugs is only 3.4% compared to 20.9% in other disease types (Wong et al, 2018). One contributing factor to this issue is the testing systems used, with two-dimensional (2D) monolayer assay formats as the traditional mainstay of high throughput screening. Although 2D monolayer assays have identified many successful drugs, it is increasingly recognized that they do not accurately model key aspects of the three-dimensional (3D) tumor environment. Therefore, the adoption of high throughput screening approaches using 3D assays to complement 2D approaches could substantially improve prediction of clinical outcomes and reduce the high failure rate of cancer drugs in clinical trials.
A major study has been undertaken to gain a better understanding of thousands of mutations in the BRCA1 gene - a key gene in breast and ovarian cancers.
A revolution is under way in functional genomics which is spearheaded by the CRISPR-Cas9 system and its application to pooled genetic screening. Remarkable new tools, made possible by dCas9, are coming to fruition that will allow for a new kind of interrogation of gene function, allowing us to ask more sophisticated questions about the biology of drug targets.
This blog explores how a selection of HAP1 knockout cell lines were used to confirm the involvement of DDR pathways in compounds mode of action, demonstrating opportunities for the exploitation of synthetic lethal interactions.